Childhood Solid Tumor Network

  

Freely sharing resources to advance science and cures

 

The Childhood Solid Tumor Network (CSTN) offers the world's largest and most comprehensive collection of scientific resources for researchers studying pediatric solid tumors and related biology.

By freely sharing unique tools with no obligation to collaborate, we aim to promote global discovery and new treatments for pediatric patients with poorly understood and difficult-to-treat solid tumors.

Requesting solid tumor resources

Elizabeth Stewart, MD

Available Resources

Michael Dyer, PhD, and Alberto Pappo, MD

Frequently Asked Questions

About the Childhood Solid Tumor Network

Childhood solid tumors are often difficult to study and treat because they are rare and originate in the complex biological context of developing organs. The CSTN was established to disseminate resources and data that have been developed at St. Jude Children’s Research Hospital, with the aim of stimulating basic research and speeding translation to the clinic.

The effort was launched in 2013 by Howard Hughes Medical Institute investigator Michael Dyer, PhD, of St. Jude Developmental Neurobiology, and Alberto Pappo, MD, of St. Jude Oncology.

For more information, contact us: CSTN@stjude.org

 

CSTN request metrics

Last updated March 30, 2019.

Total Requests Total Vials Sent Out  Principal Investigators Institutions Countries
507 1354 200 99 16
 

References

 

Read about our new method to produce orthotopic patient-derived xenografts. All O-PDX models and associated data are available. Please cite this reference in publications resulting from use of CSTN resources:

Stewart E, Federico S, Chen X, et al. Orthotopic patient-derived xenografts of paediatric solid tumoursNature 549(7670):96-100, 2017.

Other research articles

The Childhood Solid Tumor Network repository of PDXs has been invaluable to studying rare cancers, including rhabdomyosarcoma, a devastating cancer of muscle. The resource is open-access, free and comprises a large collection of well-annotated pediatric samples.

David M. Langenau, Ph.D. 
Associate Professor, Pathology, Harvard Medical School 
Assistant Molecular Pathologist, Molecular Pathology, Massachusetts General Hospital